K. Shakeri‐Nejad

发表

Are Not Affected by Moderate Hepatic Impairment Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor,

K. Rathgen, J. Stangier, H. Stähle, 2011 .

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

K. Rathgen, J. Stangier, H. Stähle, 2008, Journal of clinical pharmacology.

Drug interactions during therapy with three major groups of antimicrobial agents

R. Stahlmann, K. Shakeri-Nejad, K. Shakeri‐Nejad, 2006, Expert opinion on pharmacotherapy.

Elucidation of the Metabolic Pathways and the Resulting Multiple Metabolites of Almorexant, a Dual Orexin Receptor Antagonist, in Humans

W. Wagner-Redeker, G. Hopfgartner, A. Treiber, 2013, Drug Metabolism and Disposition.

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

E. Legangneux, N. Pezous, L. Mooney, 2015, Clinical therapeutics.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes

S. Neelakantham, Andrea J Feller, Swati Dumitras, 2019, European Journal of Clinical Pharmacology.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects

G. Rossato, E. Legangneux, P. Pal, 2018, Clinical Pharmacokinetics.

Impact of siponimod on vaccination response in a randomized, placebo-controlled study

E. Legangneux, T. Marbury, Zhenzhong Su, 2017, Neurology: Neuroimmunology & Neuroinflammation.

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence

F. Dahlke, M. Bigaud, K. Shakeri-Nejad, 2022, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data

S. Neelakantham, C. Kolly, K. Shakeri-Nejad, 2021, Psychopharmacology.

Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects.

E. Legangneux, M. Gutierrez, N. Pezous, 2016, Clinical therapeutics.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

D. Hoyer, G. Bilbe, K. Lingenhoehl, 2015, British journal of pharmacology.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes

S. Neelakantham, Andrea J Feller, Swati Dumitras, 2019, European Journal of Clinical Pharmacology.

ACh receptor partial agonist: pharmacological characterization and phase I

D. Hoyer, G. Bilbe, C. Pryce, 2015 .

Tolerability and Pharmacokinetics of ACT-280778, a Novel Nondihydropyridine Dual L/T-type Calcium Channel Blocker: Early Clinical Studies in Healthy Male Subjects Using Adaptive Designs

Markus S. Mueller, B. Sanderson, J. Dingemanse, 2014, Journal of cardiovascular pharmacology.